Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Research Alliance Corp. IIRACB · Entity 122733 | Director | March 17, 2021 | March 18, 2021 |
| TALPHERA, INC.TLPH · Entity 7102 | Director | June 22, 2026 | June 24, 2026 |
| Whitehawk Therapeutics, Inc.ARPO · Entity 6074 | Director · Chief Executive Officer | May 14, 2019 | May 16, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Research Alliance Corp. II
Report date March 17, 2021 · Filed March 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
Holding disclosure · report date 2021-03-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 30,000 F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
TALPHERA, INC.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,959 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 5,100 · Balance 13,959 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-06-21 | Direct | 30,700 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 30,700 · Balance 30,700 F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.
F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company.
Whitehawk Therapeutics, Inc.
Report date May 14, 2019 · Filed May 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2029-05-14 | Direct | 709,050 |
Reported balance
After 2019-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-14 · Grant · Acquired 709,050 · Balance 709,050 F1: 50% of the shares shall vest on June 30, 2020 and the remaining 50% shall vest on June 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the shares shall vest on June 30, 2020 and the remaining 50% shall vest on June 30, 2021.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dicerna Pharmaceuticals Inc
Report date December 28, 2021 · Filed December 29, 2021
Section 16 reporting ended · disclosed 2021-12-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 1
1 source rowRow 1 · 2021-12-28 · Other · Disposed 16,157 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2: Prior to the Effective Time, the Reporting Person beneficially owned 16,157 Shares, which reflects the correction of a clerical error of 90 shares previously over-reported and shares transferred to the Reporting Person's ex-spouse pursuant to a divorce decree. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-28 · Disposition to issuer · Disposed 3,333 · Balance 0 F3: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F4: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.26 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.42 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.08 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.44 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.30 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.73 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.61 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.47 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: Prior to the Effective Time, the Reporting Person beneficially owned 16,157 Shares, which reflects the correction of a clerical error of 90 shares previously over-reported and shares transferred to the Reporting Person's ex-spouse pursuant to a divorce decree.
F3: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.
F4: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 24, 2026 21:12 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 30,700 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001190418-26-000002 · form4-06242026_090614.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,700 Underlying: Common Stock · 30,700 shares Expires 2036-06-21 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 21:12 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantCommon Stock | 5,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001190418-26-000002 · form4-06242026_090614.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,959 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| October 23, 2025 Filed Oct 24, 2025 20:50 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 25,600 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001190418-25-000005 · form4-10242025_081032.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2035-10-22 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. Read SEC document |
| October 23, 2025 Filed Oct 24, 2025 20:50 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantCommon Stock | 4,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001190418-25-000005 · form4-10242025_081032.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,859 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 23:13 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 13,044 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001415889-24-018075 · form4-06242024_110610.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,044 Underlying: Common Stock · 13,044 shares Expires 2034-06-23 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 23:13 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantCommon Stock | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018075 · form4-06242024_110610.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,592 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| October 10, 2023 Filed Dec 13, 2023 21:35 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 3,487 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001209191-23-058489 · doc4.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,487 Underlying: Common Stock · 3,487 shares Expires 2033-10-10 F4 · derivative.exercise_date: 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| October 10, 2023 Filed Dec 13, 2023 21:35 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 581 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058489 · doc4.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,418 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. F3 · balance_after: Effective on October 25, 2022, the issuer effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| July 15, 2022 Filed Jul 15, 2022 23:29 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001209191-22-042307 · doc4.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2032-07-14 F3 · derivative.exercise_date: 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| July 15, 2022 Filed Jul 15, 2022 23:29 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042307 · doc4.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,750 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:20 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $30.47 | Not disclosed |
DisclosureSEC source: 0001399529-21-000201 · wf-form4_164081283175966.xml · derivative · entry 11 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:20 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $21.61 | Not disclosed |
DisclosureSEC source: 0001399529-21-000201 · wf-form4_164081283175966.xml · derivative · entry 10 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:20 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $18.73 | Not disclosed |
DisclosureSEC source: 0001399529-21-000201 · wf-form4_164081283175966.xml · derivative · entry 9 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:20 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $16.30 | Not disclosed |
DisclosureSEC source: 0001399529-21-000201 · wf-form4_164081283175966.xml · derivative · entry 8 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:20 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $15.44 | Not disclosed |
DisclosureSEC source: 0001399529-21-000201 · wf-form4_164081283175966.xml · derivative · entry 7 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:20 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $13.87 | Not disclosed |
DisclosureSEC source: 0001399529-21-000201 · wf-form4_164081283175966.xml · derivative · entry 6 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:20 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $13.08 | Not disclosed |
DisclosureSEC source: 0001399529-21-000201 · wf-form4_164081283175966.xml · derivative · entry 5 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:20 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $3.42 | Not disclosed |
DisclosureSEC source: 0001399529-21-000201 · wf-form4_164081283175966.xml · derivative · entry 4 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:20 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $3.26 | Not disclosed |
DisclosureSEC source: 0001399529-21-000201 · wf-form4_164081283175966.xml · derivative · entry 3 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:20 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Disposition to issuerRestricted Stock Units · Derivative | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001399529-21-000201 · wf-form4_164081283175966.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F4 · price: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). F4 · derivative.expiration_date: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:20 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | OtherCommon Stock | 16,157 | $38.25 | $618,005.25 |
DisclosureSEC source: 0001399529-21-000201 · wf-form4_164081283175966.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2 · shares: Prior to the Effective Time, the Reporting Person beneficially owned 16,157 Shares, which reflects the correction of a clerical error of 90 shares previously over-reported and shares transferred to the Reporting Person's ex-spouse pursuant to a divorce decree. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 21:25 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001209191-21-041560 · doc4.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-16 F3 · derivative.exercise_date: 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 21:25 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041560 · doc4.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 03, 2021 Filed Jun 8, 2021 01:36 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $30.47 | $0.00 |
DisclosureSEC source: 0001399529-21-000111 · wf-form4_162311613423290.xml · derivative · entry 4 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-02 F4 · derivative.exercise_date: This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option will vest in full on the next regularly scheduled annual meeting of the stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 03, 2021 Filed Jun 8, 2021 01:36 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001399529-21-000111 · wf-form4_162311613423290.xml · derivative · entry 3 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting. F3 · derivative.expiration_date: Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting. Read SEC document |
| June 03, 2021 Filed Jun 8, 2021 01:36 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001399529-21-000111 · wf-form4_162311613423290.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021. F2 · derivative.expiration_date: Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021. Read SEC document |
| June 03, 2021 Filed Jun 8, 2021 01:36 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Exercise / conversionCommon Stock | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001399529-21-000111 · wf-form4_162311613423290.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 10, 2020 Filed Feb 16, 2021 12:07 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | OtherCommon Stock | 10,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001399529-21-000033 · wf-form5_161347721171564.xml · nonDerivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,738 F1 · kind: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to the Reporting Person. Read SEC document |
| August 26, 2020 Filed Feb 16, 2021 12:07 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | OtherCommon Stock | 15,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001399529-21-000033 · wf-form5_161347721171564.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,601 F1 · kind: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to the Reporting Person. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 23:15 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001209191-20-037079 · doc4.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-15 F3 · derivative.exercise_date: 100% of the option shares subject to the option shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 23:15 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037079 · doc4.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 00:13 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $21.61 | $0.00 |
DisclosureSEC source: 0000899243-20-016741 · doc4.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-14 F2 · derivative.exercise_date: This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option vests in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 00:13 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-016741 · doc4.xml · derivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:03 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-19-039020 · doc4.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-25 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:03 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039020 · doc4.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company. Read SEC document |
| June 20, 2019 Filed Jun 22, 2019 00:01 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0000899243-19-017861 · doc4.xml · derivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-20 F1 · derivative.exercise_date: This option vests monthly over 12 months from June 20, 2019 ("Grant Date") in substantially equal monthly installments, provided that the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each such date or, if earlier, such annual meeting. Read SEC document |
| May 14, 2019 Filed May 16, 2019 21:15 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 709,050 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0000899243-19-013769 · doc4.xml · derivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709,050 Underlying: Common Stock · 709,050 shares Expires 2029-05-14 F1 · derivative.exercise_date: 50% of the shares shall vest on June 30, 2020 and the remaining 50% shall vest on June 30, 2021. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:52 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 365,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0000899243-19-004274 · doc4.xml · derivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,000 Underlying: Common Stock · 365,000 shares Expires 2029-02-15 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date. Read SEC document |
| November 12, 2018 Filed Nov 14, 2018 21:25 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 30,000 | $2.01 | $60,300.00 |
DisclosureSEC source: 0000899243-18-028925 · doc4.xml · nonDerivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,967 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.95 to $2.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| November 09, 2018 Filed Nov 14, 2018 21:25 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 1,967 | $1.95 | $3,835.65 |
DisclosureSEC source: 0000899243-18-028925 · doc4.xml · nonDerivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,967 Read SEC document |
| June 21, 2018 Filed Jun 26, 2018 01:00 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0000899243-18-018022 · doc4.xml · derivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: This option vests monthly over 12 months from June 21, 2018 ("Grant Date") in substantially equal monthly installments, provided that the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each such date or, if earlier, such annual meeting. Read SEC document |
| June 14, 2018 Filed Feb 7, 2019 22:33 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001209191-19-008170 · doc5.xml · derivative · entry 5 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-14 F1 · security: Issued pursuant to the 2011 Equity Incentive Plan. F2 · security: Transactions were previously reported on Form 4, but were inadvertently filed using incorrect CIK and CCC numbers which resulted in the reports appearing incorrectly as a report of a person different from the Reporting Person. This Form 5 is being filed to identify correctly these past transactions as the Reporting Person's transactions and to reflect accurately the Reporting Person's beneficial ownership holdings in the Issuer. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Optionee's Continuous Service on the Company's Board of Directors. F5 · derivative.exercise_date: 100% Acceleration upon Change of Control. Read SEC document |
| April 23, 2018 Filed Apr 26, 2018 00:28 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0000899243-18-010751 · doc4.xml · derivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-04-23 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 22:13 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 586,012 | $5.50 Strike: $5.50 | $3,223,066.00 |
DisclosureSEC source: 0000899243-17-029055 · doc4.xml · derivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 586,012 shares Expires 2027-12-01 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date. Read SEC document |
| July 18, 2017 Filed Jul 24, 2017 22:00 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0000899243-17-018769 · doc4.xml · derivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-07-18 F1 · derivative.exercise_date: This option vests monthly over 12 months from July 11, 2017 in substantially equal monthly installments, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| June 15, 2017 Filed Feb 7, 2019 22:33 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-19-008170 · doc5.xml · derivative · entry 4 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-14 F1 · security: Issued pursuant to the 2011 Equity Incentive Plan. F2 · security: Transactions were previously reported on Form 4, but were inadvertently filed using incorrect CIK and CCC numbers which resulted in the reports appearing incorrectly as a report of a person different from the Reporting Person. This Form 5 is being filed to identify correctly these past transactions as the Reporting Person's transactions and to reflect accurately the Reporting Person's beneficial ownership holdings in the Issuer. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Optionee's Continuous Service on the Company's Board of Directors. F5 · derivative.exercise_date: 100% Acceleration upon Change of Control. Read SEC document |
| June 21, 2016 Filed Feb 7, 2019 22:33 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001209191-19-008170 · doc5.xml · derivative · entry 3 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-06-20 F1 · security: Issued pursuant to the 2011 Equity Incentive Plan. F2 · security: Transactions were previously reported on Form 4, but were inadvertently filed using incorrect CIK and CCC numbers which resulted in the reports appearing incorrectly as a report of a person different from the Reporting Person. This Form 5 is being filed to identify correctly these past transactions as the Reporting Person's transactions and to reflect accurately the Reporting Person's beneficial ownership holdings in the Issuer. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 23, 2015 Filed Feb 7, 2019 22:33 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001209191-19-008170 · doc5.xml · derivative · entry 2 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-06-22 F1 · security: Issued pursuant to the 2011 Equity Incentive Plan. F2 · security: Transactions were previously reported on Form 4, but were inadvertently filed using incorrect CIK and CCC numbers which resulted in the reports appearing incorrectly as a report of a person different from the Reporting Person. This Form 5 is being filed to identify correctly these past transactions as the Reporting Person's transactions and to reflect accurately the Reporting Person's beneficial ownership holdings in the Issuer. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| July 24, 2014 Filed Feb 7, 2019 22:33 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.22 | $0.00 |
DisclosureSEC source: 0001209191-19-008170 · doc5.xml · derivative · entry 1 HOFFMAN STEPHEN J · CIK 0001190418 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2024-07-23 F1 · security: Issued pursuant to the 2011 Equity Incentive Plan. F2 · security: Transactions were previously reported on Form 4, but were inadvertently filed using incorrect CIK and CCC numbers which resulted in the reports appearing incorrectly as a report of a person different from the Reporting Person. This Form 5 is being filed to identify correctly these past transactions as the Reporting Person's transactions and to reflect accurately the Reporting Person's beneficial ownership holdings in the Issuer. F3 · derivative.exercise_date: Fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.